Sort   by:  
 Page size 
UnknownAngiotensin II Type 1 Receptor Mechanoactivation Involves RGS5 (Regulator of G Protein Signaling 5) in Skeletal Muscle Arteries: Impaired Trafficking of RGS5 in Hypertension.
Not available
S-EPMC5683087 | biostudies-literature
UnknownAdverse organogenesis and predisposed long-term metabolic syndrome from prenatal exposure to fine particulate matter.
Not available
S-EPMC6575589 | biostudies-literature
UnknownCanagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Not available
S-EPMC5198289 | biostudies-literature
UnknownEfficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.
Not available
S-EPMC5685027 | biostudies-literature
UnknownStudy protocol: randomized controlled trial of an individualized music intervention for people with dementia in the home care setting.
Not available
S-EPMC10967058 | biostudies-literature
UnknownA post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Not available
S-EPMC4974722 | biostudies-literature
UnknownEffects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Not available
S-EPMC4701850 | biostudies-literature
UnknownEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.
Not available
S-EPMC4855968 | biostudies-literature
UnknownMutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis.
Not available
S-EPMC3575525 | biostudies-literature
UnknownCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Not available
S-EPMC3747923 | biostudies-literature
Sort   by:  
 Page size